The effect of somatostatin on thyrotropin releasing factor or luteinizing hormone releasing factor induced growth hormone (GH) release was studied in 4 acromegalic patients. The increase in plasma GH induced by these nonspecific releasing factors still occurred despite somatostatin administration at a dose double the one sufficient to markedly decrease plasma GH levels in acromegalics and to completely suppress hypoglycemia or arginine induced GH release in normals.
|Number of pages||4|
|Journal||Journal of Clinical Endocrinology and Metabolism|
|Publication status||Published - 1974|
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism